StockData

Caribou Biosciences vs Lineage Cell Therapeutics

CRBU and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRBU and LCTX compare

Lineage Cell Therapeutics is the larger company, worth 5.3 times as much as Caribou Biosciences ($201M against $37.8M).

Lineage Cell Therapeutics grew revenue faster over the last twelve months (19.9% versus 10.0% for Caribou Biosciences).

Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of −247% compared with −1030% at Caribou Biosciences.

Caribou Biosciences scores higher on the StockData Score (9 against 8 for Lineage Cell Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRBULCTX
Size and price
Market cap$37.8M$201M
Share price$0.353$0.795
Change, 1 year−82.2%−55.8%
Change, 5 years−98.0%−60.0%
Beta (5Y)1.361.21
Employees9777
StockData Score
Total score9 (better)8
Valuation score3 (better)0
Growth score11
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S3.8× (better)15.4×
P/B0.4× (better)3.3×
FCF yield−253%−12.1% (better)
Fair value$1.29$0.657
Margin of safety72.6% (better)−21.0%
Growth
Revenue growth (TTM)10.0%19.9% (better)
Revenue growth, 5Y average−2.0%51.5% (better)
Profitability
Operating margin−1091%−205% (better)
Net margin−1030%−247% (better)
FCF margin−954%−186% (better)
Return on equity−78.3%−59.0% (better)
Return on invested capital–−262%
Financial health
Debt / equity0.000.00
Current ratio6.496.61 (better)
Altman Z-score−7.46−3.80 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield−64.0%–
Shareholder yield−64.0%0.00% (better)
Ownership
Held by institutions45.5%46.1%
Held by insiders5.7%74.4%
Insider net buying, 12 months−$47.5K$24.4K (better)
Short interest, % of float14.7%37.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.